- Home
- Unravelling the Pathways to Early Intervention in ATTR-CM
Unravelling the Pathways to Early Intervention in ATTR-CM
- Amyloidosis
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
This course explores the critical steps in recognising and managing transthyretin amyloid cardiomyopathy (ATTR-CM) at an early stage. The expert faculty share insights on current stabilising agents, examine disease progression trajectories and discuss emerging therapies.
Gain practical insights into optimising patient outcomes through timely intervention and evolving management strategies.
Support Statement
This symposium is supported by an unrestricted educational grant from Bayer.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Unravelling the Pathways to Early Intervention in ATTR-CM’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion
Target Audience
- Cardiologists
- Heart Failure Specialists
- Cardiac Electrophysiology Specialists
- Haematologists
- Cardiac Nurse Practitioners
- Physician Assistants
- Primary Care
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review the binding affinity for current stabilising agents
- Recall the trajectory of disease progression in ATTR-CM
- Discuss future options for individuals who progress on treatment
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Part 1 | Introduction | 2m 19s | Julian Gillmore Margot Davis Ahmad Masri |
| Part 2 | Case Study | 10m 58s | Ahmad Masri |
| Part 3 | Managing Disease Early | 8m 11s | Julian Gillmore |
| Part 4 | ATTR Stabilisation: Current Standard of Care | 11m 43s | Margot Davis |
| Part 5 | Discussion: What Are Our Future Options? | 12m 55s | Julian Gillmore Margot Davis Ahmad Masri |
Discussion: What Are Our Future Options?
Duration: 12m 55s
Speakers: Julian Gillmore Margot Davis Ahmad Masri
Unravelling the Pathways to Early Intervention in ATTR-CM's programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
Related Courses
- 1.00
Published:
Learning objectives
- Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
- List red flags indicating the presence of ATTR amyloidosis
- Identify patients who should undergo detailed diagnosis work-up or referral
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 1.00
Published:
Learning objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
- Recall the limitations of existing therapies for ATTR-CM
- List the advantages of emerging classes of agents being evaluated in ATTR-CM